Wednesday, February 04, 2026 9:33:16 PM
The Basecamp Research platform is called aiPGI and powered by EDEN evolutionary AI models (developed with NVIDIA). It ''learns the language of DNA and patterns of evolution.'' The models generate active insertion proteins tailored to target loci in the human genome using just the target sequence.
So rather than evolving or modifying natural recombinases, Basecamp's EDEN models are trained on massive evolutionary datasets to generate proteins with desired insertion activity. This aims to go beyond optimisation with the AI inventing new sequence solutions for insertion enzymes tailored to specific sites, potentially covering a much wider landscape of targets compared to manually (with directed evolution, rational design of recombinases, and/or protein engineering) evolved recombinases.
So rather than evolving or modifying natural recombinases, Basecamp's EDEN models are trained on massive evolutionary datasets to generate proteins with desired insertion activity. This aims to go beyond optimisation with the AI inventing new sequence solutions for insertion enzymes tailored to specific sites, potentially covering a much wider landscape of targets compared to manually (with directed evolution, rational design of recombinases, and/or protein engineering) evolved recombinases.
Recent SGMO News
- Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) • GlobeNewswire Inc. • 04/30/2026 12:05:00 PM
- Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market • IH Market News • 04/29/2026 02:45:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 12:37:29 PM
- Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market • GlobeNewswire Inc. • 04/29/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:07:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 08:01:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 11:08:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call • GlobeNewswire Inc. • 03/19/2026 08:03:00 PM
- Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 02:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:35:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/04/2026 01:31:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:07:22 PM
